Circulating miRNA markers show promise as new prognosticators for multiple myeloma
A Rocci, CC Hofmeister, S Geyer, A Stiff, M Gambella… - Leukemia, 2014 - nature.com
A Rocci, CC Hofmeister, S Geyer, A Stiff, M Gambella, L Cascione, J Guan, DM Benson…
Leukemia, 2014•nature.comHowever, we hypothesize that in some cases, JAK2 inhibitormediated effects on stem cells
might be advantageous; for example, as an adjunct to stem cell transplantation. However, in
summary our data support the notion that JAK2 has a critical role in normal hematopoiesis,
and current and future therapeutic approaches aimed at targeting JAK2 need to consider
effects on stem cell function and the relative inhibitory effects on normal and malignant cells,
which might limit, or even abrogate, therapeutic efficacy.
might be advantageous; for example, as an adjunct to stem cell transplantation. However, in
summary our data support the notion that JAK2 has a critical role in normal hematopoiesis,
and current and future therapeutic approaches aimed at targeting JAK2 need to consider
effects on stem cell function and the relative inhibitory effects on normal and malignant cells,
which might limit, or even abrogate, therapeutic efficacy.
However, we hypothesize that in some cases, JAK2 inhibitormediated effects on stem cells might be advantageous; for example, as an adjunct to stem cell transplantation. However, in summary our data support the notion that JAK2 has a critical role in normal hematopoiesis, and current and future therapeutic approaches aimed at targeting JAK2 need to consider effects on stem cell function and the relative inhibitory effects on normal and malignant cells, which might limit, or even abrogate, therapeutic efficacy.
nature.com
